Biomarker of metformin

Metformin is a first-line, anti-diabetic agent prescribed to over 150 million people worldwide. The main effect of metformin is to suppress glucose production in the liver; however, there is no reliable biomarker to assess the effectiveness of metformin administration. In previous studies, He and colleagues demonstrated that phosphorylation of CBP at S436 is important for the regulation of hepatic glucose production by metformin. In this study, they go on to demonstrate that CBP phosphorylation in white blood cells may be used as a biomarker for metformin action in the liver.

Read the full article at He et al. (2014) Journal of Endocrinology 221 363–369; DOI:10.1530